COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03187431
Recruitment Status : Unknown
Verified June 2017 by Aliae AR Mohamed Hussein, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : June 15, 2017
Last Update Posted : June 15, 2017
Information provided by (Responsible Party):
Aliae AR Mohamed Hussein, Assiut University

Brief Summary:
Currently, the application status of MSCs as treatment modalities in IPF is still in its infancy and remains exploratory. Although a number of safety and efficacy clinical trials of MSCs as therapeutic options in immune-mediated and cardiac diseases have already been published with tantalizing results, to our disappointment, pulmonary and critical care medicine have traditionally lagged behind other therapeutic and research fields including hematology, gastroenterology and cardiology in translational studies of the use of reparative cells

Condition or disease Intervention/treatment Phase
Stem Cell Transplant Complications Biological: autologous bone marrow mesenchymal stem cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mesenchymal Stem Cell as Therapeutic Modality in Interstitial Pulmonary Fibrosis
Estimated Study Start Date : December 11, 2017
Estimated Primary Completion Date : October 1, 2018
Estimated Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IPF patients
autologous bone marrow mesenchymal stem cells
Biological: autologous bone marrow mesenchymal stem cells
intravenous infusion

Primary Outcome Measures :
  1. number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation [ Time Frame: 6 months ]
    safety and side effects

Secondary Outcome Measures :
  1. Post therapy diffusing capacity of CO% (DLCO)predicted [ Time Frame: 6-12 months ]
    Efficacy of procedure

  2. post therapy forced vital capacity (FVC)% predicted. [ Time Frame: 6-12 months ]
    efficacy of the procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 75 years (both inclusive)
  • high-resolution computed tomography (HRCT) scan that is very suggestive or consistent with a probable diagnosis of usual interstitial pneumonia.
  • Bronchoalveolar lavage must be performed at any time before inclusion and must have failed to show features supporting alternative diagnoses.
  • The duration of the disease should be more than three months, and bibasilar inspiratory crackles should be present.
  • dyspnea score of at least 2 on a scale of 0 (minimum) to 10 (maximum).
  • FVC > 50% of the predicted normal value and DLco > 35% of the predicted value.
  • Patients under treatment with n-acetylcysteine or pirfenidone should discontinue drug and enter a wash-out period for at least 6 weeks prior study enrolment.

Exclusion Criteria:

  • FVC < 50% predicted normal value and DLCO < 35%predicted normal value.
  • lung cancer or with an evidence of active malignancyfor at least 5 years.
  • uncontrolled heart failure.
  • renal failure
  • hepatic failure,
  • neurological abnormalities including stroke and myasthenia Gravis
  • Anti-coagulants therapy.
  • Active infections.
Layout table for additonal information
Responsible Party: Aliae AR Mohamed Hussein, Prof. Dr. Aliae AR Mohamed-Hussein, Professor of Pulmonology, Assiut University Identifier: NCT03187431    
Other Study ID Numbers: AssiutU4
First Posted: June 15, 2017    Key Record Dates
Last Update Posted: June 15, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aliae AR Mohamed Hussein, Assiut University:
Stem cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Lung Diseases
Respiratory Tract Diseases